Lee M. Krug

Lee M. Krug

Auto-generated profile, based on publicly available information

Lee M. Krug

Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
LKLee M. Krug
Lee M. Krug
HPHarvey Pass
Harvey Pass
VRValerie W. Rusch
Valerie W. Rusch
HKHedy L. Kindler
Hedy L. Kindler
DSDavid J. Sugarbaker
David J. Sugarbaker
NVNicholas J. Vogelzang
Nicholas J. Vogelzang
Purpose: Neoadjuvant pemetrexed plus cisplatin was administered, followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT), to assess the feasibility and efficacy of trimodality therapy in stage I to III malignant pleural mesothelioma. Patients and Methods: Requirements included stage T1-3 N0-2 disease, no prior surgical resection, adequate organ function (including predicted postoperative forced expiratory volume in 1 second ≥ 35%), and performance status 0 to 1. Patients received pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 for four cycles. Patients without disease progression underwent EPP followed by RT (54 Gy). The primary end point was pathologic complete response (pCR) rate. Results: Seventy-seven patients received chemotherapy. All four cycles were administered to 83% of patients. The radiologic response rate was 32.5% (95% CI, 22.2 to 44.1). Fifty-seven patients proceeded to EPP, which was completed in 54 patients. Three pCRs were observed (5% of EPP). Forty of 44 patients completed irradiation. Median survival in the overall population was 16.8 months (95% CI, 13.6 to 23.2 months; censorship, 33.8%). Patients completing all therapy had a median survival of 29.1 months and a 2-year survival rate of 61.2%. Radiologic response of complete or partial response was associated with a median survival of 26.0 months compared with 13.9 months for patients with stable disease or progressive disease (P = .05). Conclusion: This multicenter trial showed that trimodality therapy with neoadjuvant pemetrexed plus cisplatin is feasible with a reasonable long-term survival rate, particularly for patients who completed all therapy. Radiologic response to chemotherapy, but not sex, histology, disease stage, or nodal status, was associated with improved survival.

1 April 2015 in The Lancet Oncology
Verified
Journal Article
Closed access
LKLee M Krug
Lee M Krug
HKHedy L Kindler
Hedy L Kindler
HCHilary Calvert
Hilary Calvert
CMChristian Manegold
Christian Manegold
ATAnne S Tsao
Anne S Tsao
PBPaul Baas
Paul Baas

5 April 2005 in Cancer
Verified
Journal Article
Closed access
PDF file
LKLee M. Krug
Lee M. Krug
JCJohn P. Crapanzano
John P. Crapanzano
CAChristopher G. Azzoli
Christopher G. Azzoli
VMVincent A. Miller
Vincent A. Miller
NRNaiyer Rizvi
Naiyer Rizvi
RHRobert T. Heelan
Robert T. Heelan

8 June 2010 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
LKLee M. Krug
Lee M. Krug
TDTao Dao
Tao Dao
ABAndrew B. Brown
Andrew B. Brown
PMPeter Maslak
Peter Maslak
WTWilliam Travis
William Travis
DSDavid A. Scheinberg
David A. Scheinberg

1 January 2006 in Clinical Lung Cancer
Verified
Journal Article
Closed access
LKLee M. Krug
Lee M. Krug
TCTracy Curley
Tracy Curley
LSLawrence Schwartz
Lawrence Schwartz
SRStacie Richardson
Stacie Richardson
PMPaul Marks
Paul Marks
WKW. Kevin Kelly
W. Kevin Kelly

15 September 2004 in Clinical Cancer Research
Verified
Journal Article
Closed access
LKLee M. Krug
Lee M. Krug
GRGovind Ragupathi
Govind Ragupathi
CHChandra Hood
Chandra Hood
MKMark G. Kris
Mark G. Kris
VMVincent A. Miller
Vincent A. Miller
PLPhilip O. Livingston
Philip O. Livingston
Purpose: Immunotherapy directed toward cell surface antigens may provide a novel approach to the eradication of chemoresistant micrometastatic disease in patients with small-cell lung cancer (SCLC). Studies in SCLC cell lines and human tissues suggest that the ganglioside fucosyl GM1 is an abundant yet specific target. A prior clinical study demonstrated the potent immunogenicity of fucosyl GM-1 derived from bovine thyroid gland, conjugated to keyhole limpet hemocyanin (KLH) and administered with QS-21 adjuvant. Experimental Design: We tested the immunogenicity of three different doses of a synthetic version of fucosyl-GM1 in patients with SCLC after a major response to initial therapy. The primary end point was to establish the lowest effective dose capable of inducing antibody production. Results: Five of six patients at the 30-μg dose and three of five patients at the 10-μg dose mounted IgM responses of 1:80 or greater. These antibodies were confirmed by flow cytometry in seven of eight cases. None of the patients at the 3-μg dose had titers above 1:80. One patient at the 30-μg dose had an IgG response with a titer of 1:80. The sera from six of the eight responders induced potent complement-mediated cytotoxicity of tumor cells. Conclusions: Vaccination with the synthetic fucosyl GM1-KLH conjugate induces an IgM antibody response against fucosyl GM1 and tumor cells expressing fucosyl GM1, comparable with the response induced by the bovine derivative. We plan to combine synthetic fucosyl GM1 vaccine at a dose of 30 μg with vaccines against three other antigens—GM2, Globo H, and polysialic acid—to test in patients with SCLC after initial chemotherapy.